Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Patient groups push back against Gilead pricey HIV prevention treatment Descovy

      Patient groups push back against Gilead pricey HIV prevention treatment Descovy

      Medical Dialogues Bureau10 Aug 2019 9:15 AM IST
      Such groups have traditionally lobbied for insurance coverage of newer HIV drugs regardless of expense. But at least three U.S. organizations now...
      Alembic Pharma gets tentative USFDA nod for Bimatoprost Ophthalmic Solution

      Alembic Pharma gets tentative USFDA nod for Bimatoprost Ophthalmic Solution

      Medical Dialogues Bureau9 Aug 2019 10:00 AM IST
      Alembic Pharma's Bimatoprost Ophthalmic Solution is therapeutically equivalent to the reference listed drug product Lumigan ophthalmic solution 0.01...
      Meril Life Sciences gets European Conformity mark for Bioresorbable Scaffold MeRes100

      Meril Life Sciences gets European Conformity mark for Bioresorbable Scaffold MeRes100

      Medical Dialogues Bureau9 Aug 2019 9:45 AM IST
      Meril Life Sciences MeRes100 has received both Drug Controller General of India(DCGI) and CE (European Conformity) marketing approval. New Delhi:...
      Lupin net profit rises 49.46 percent to Rs 303 crore for June quarter

      Lupin net profit rises 49.46 percent to Rs 303 crore for June quarter

      Medical Dialogues Bureau9 Aug 2019 9:30 AM IST
      Consolidated sales for the quarter under review also rose to Rs 4,355.83 crore as against Rs 3,774.57 crore during the same period a year ago, Lupin...
      Knew about Zolgensma data problems before US approval: Novartis

      Knew about Zolgensma data problems before US approval: Novartis

      Medical Dialogues Bureau9 Aug 2019 9:15 AM IST
      "We made the decision to progress our quality investigation prior to informing FDA and other regulatory authorities so that we could provide the best...
      Bayer buys BlueRock in USD 600 million bet on stem cell therapies

      Bayer buys BlueRock in USD 600 million bet on stem cell therapies

      Medical Dialogues Bureau9 Aug 2019 9:00 AM IST
      FRANKFURT: German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics, stepping up...
      Bayer Rivaroxaban tablets win CDSCO Committee nod for waiver of local clinical trial; directed to carry Phase IV trial

      Bayer Rivaroxaban tablets win CDSCO Committee nod for waiver of local clinical trial; directed to carry Phase IV trial

      Medical Dialogues Bureau8 Aug 2019 5:28 PM IST
      New Delhi: The apex drug regulatory body, Central Drugs Standard Control Organisation's (CDSCO) Technical Committee has recommended for grant of...
      Cadila Healthcare gets OAI letter from USFDA for Moraiya facility

      Cadila Healthcare gets OAI letter from USFDA for Moraiya facility

      Medical Dialogues Bureau8 Aug 2019 10:00 AM IST
      The company has received a letter from the USFDA classifying the inspection conducted at its Moraiya facility from April 22 to May 3 as OAI, Cadila...
      GSK ends Ebola vaccine RnD; transfers license to US institute

      GSK ends Ebola vaccine RnD; transfers license to US institute

      Medical Dialogues Bureau8 Aug 2019 9:30 AM IST
      GSK had put its Ebola vaccine work on hold after it was unable to progress the product through the final stage, or Phase III, clinical trials toward...
      Novartis concealed data problem before seeking approval for USD 2.1 million gene therapy Zolgensma: USFDA

      Novartis concealed data problem before seeking approval for USD 2.1 million gene therapy Zolgensma: USFDA

      Medical Dialogues Bureau8 Aug 2019 9:15 AM IST
      The FDA said in a statement that AveXis Inc., the Novartis AG subsidiary that manufactures Zolgensma, told the agency five weeks after the approval of...
      Granules India arm wins USFDA approval for stimulant drug Amphetamine Sulfate tablets

      Granules India arm wins USFDA approval for stimulant drug Amphetamine Sulfate tablets

      Medical Dialogues Bureau7 Aug 2019 9:30 AM IST
      Amphetamine Sulfate tablets is a generic version of Arbor Pharmaceuticals LLC's Evekeo tablets in similar strength, it added.New Delhi: Drug firm...
      Daiichi Sankyo CEO capped USD 37 billion recovery with AstraZeneca deal: Bloomberg

      Daiichi Sankyo CEO capped USD 37 billion recovery with AstraZeneca deal: Bloomberg

      Medical Dialogues Bureau7 Aug 2019 9:10 AM IST
      Daiichi Sankyo CEO, Nakayama decided the company needed a change, so he sold the Sun Pharmaceutical stake and shifted his focus to cancer drugs,...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok